The Game Changer
Modeling and simulation in drug development could change the commercial and regulatory landscape forever… and can deliver significant business, scientific and clinical value to companies.
Month: 2016年10月
Kelley Kendle, President of Certara’s Synchrogenix Division, Named to DBT ‘Top 40 Under 40’
PRINCETON, NJ – Oct. 6, 2016 – Certara announces that Kelley Kendle, president of Synchrogenix, its medical and regulatory writing consultancy, has been named a Delaware Business Times (DBT) 40 honoree. This is an annual listing of Delaware’s influential achievers and innovators under the age of 40.
Profiling the Relationship Between Tumor-associated Macrophages and Pharmacokinetics of Liposomal Agents in Preclinical Murine Models
A Study to Examine the Relationship Between Metritis Severity and Depletion of Oxytetracycline in Plasma and Milk after Intrauterine Infusion
Metritis is a frequent problem in postpartum dairy cows. Intrauterine therapy with the antimicrobial oxytetracycline (OTC) is often used, although this therapy has not been shown to be superior to systemic therapy. The objectives of this study were to (1) determine the plasma and milk concentrations of OTC following intrauterine infusion in postpartum dairy cows … Continued
Abundance of Hepatic Transporters in Caucasians: A Meta-analysis
The aim of this study was to derive quantitative abundance values for key hepatic transporters suitable for in vitro-in vivo extrapolation (IVIVE) within a physiologically-based pharmacokinetic modeling framework. A meta-analysis was performed whereby abundance measurements, sample preparation method and donor demography were collated from literature. In order to define values for a healthy Caucasian population, … Continued
